Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD

0.98  -0.11 (-10.09%)

Fundamental Rating

2

Taking everything into account, PRLD scores 2 out of 10 in our fundamental rating. PRLD was compared to 572 industry peers in the Biotechnology industry. PRLD has a great financial health rating, but its profitability evaluates not so good. PRLD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRLD had negative earnings in the past year.
PRLD had a negative operating cash flow in the past year.
In the past 5 years PRLD always reported negative net income.
In the past 5 years PRLD always reported negative operating cash flow.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

PRLD has a worse Return On Assets (-66.69%) than 64.07% of its industry peers.
Looking at the Return On Equity, with a value of -84.07%, PRLD is in line with its industry, outperforming 50.27% of the companies in the same industry.
Industry RankSector Rank
ROA -66.69%
ROE -84.07%
ROIC N/A
ROA(3y)-44.28%
ROA(5y)-56.84%
ROE(3y)-49.84%
ROE(5y)-67.71%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PRLD has been reduced compared to 1 year ago.
The number of shares outstanding for PRLD has been increased compared to 5 years ago.
PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

PRLD has an Altman-Z score of -4.62. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
PRLD has a Altman-Z score of -4.62. This is in the lower half of the industry: PRLD underperforms 60.71% of its industry peers.
There is no outstanding debt for PRLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.62
ROIC/WACCN/A
WACCN/A
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

PRLD has a Current Ratio of 7.04. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
PRLD has a Current ratio of 7.04. This is in the better half of the industry: PRLD outperforms 67.61% of its industry peers.
PRLD has a Quick Ratio of 7.04. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
PRLD has a better Quick ratio (7.04) than 67.79% of its industry peers.
Industry RankSector Rank
Current Ratio 7.04
Quick Ratio 7.04
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.43% over the past year.
EPS 1Y (TTM)18.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.45% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.81%
EPS Next 2Y11.69%
EPS Next 3Y10.16%
EPS Next 5Y6.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.69%
EPS Next 3Y10.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (2/11/2025, 11:18:02 AM)

0.98

-0.11 (-10.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-13 2025-02-13/amc
Inst Owners54.82%
Inst Owner Change-81.69%
Ins Owners8.97%
Ins Owner Change8.42%
Market Cap53.94M
Analysts76.36
Price Target5.1 (420.41%)
Short Float %11.41%
Short Ratio6.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.88%
Min EPS beat(2)-4.88%
Max EPS beat(2)10.65%
EPS beat(4)3
Avg EPS beat(4)7.21%
Min EPS beat(4)-4.88%
Max EPS beat(4)15.1%
EPS beat(8)7
Avg EPS beat(8)11.6%
EPS beat(12)10
Avg EPS beat(12)8.79%
EPS beat(16)11
Avg EPS beat(16)5.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.43%
EPS NY rev (1m)0%
EPS NY rev (3m)3.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.98
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS0.05
BVpS2.84
TBVpS2.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.69%
ROE -84.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.28%
ROA(5y)-56.84%
ROE(3y)-49.84%
ROE(5y)-67.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 114.39%
Cap/Sales 61.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.04
Quick Ratio 7.04
Altman-Z -4.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)260.49%
Cap/Depr(5y)220.31%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.44%
EPS Next Y10.81%
EPS Next 2Y11.69%
EPS Next 3Y10.16%
EPS Next 5Y6.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.15%
EBIT Next 3Y-14.07%
EBIT Next 5YN/A
FCF growth 1Y-20.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.22%
OCF growth 3YN/A
OCF growth 5YN/A